CareDx files patent infringement lawsuit against Eurofins Viracor

CareDx files patent infringement lawsuit against Eurofins Viracor

Thursday, September 26, 2019

Patients with CKD have between 10- and 20-fold increased risk viagra discount prices of cardiac death compared with age-/gender-matched control subjects without CKD. http://cute-n-tiny.com/author/admin/page/2/ sildenafil pfizer It is also important to have a healthy erection only when you reach the ultimate point of excitement. Rather than treating the impotence, http://cute-n-tiny.com/cute-items/buy-soft-cat-toys/ get viagra online helps to prevent accumulation of seminal fluid in the reproductive system. A popular fertility speviagra on line uk t noted that just round 1% of US females are fertile when they’re on their late 20’s.

 

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware.

CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University.  This patent covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief. The suit asserts that Eurofins Viracor infringes CareDx’s patent by marketing and performance of a test that performs an analysis of cell-free DNA from a transplant patient to inform on rejection.

[huge_it_slider id=”15″]CareDx has been dedicated to continued research and development in transplantation for 20 years, and secured an exclusive license to the technology when it acquired ImmunMetrix in 2014.

“The intellectual property behind AlloSure was developed both with and for the transplant community,” said Peter Maag, CEO of CareDx. “We are prepared to vigorously defend our intellectual property where appropriate to support continued innovation in transplantation and to protect the substantial investments we have made, as well as the leadership position we have developed over many years of effort.”

Source: Company Press Release

Key Facts
    •  News CategoryLegal And Regulatory
    •  CompanyEurofins Viracor Inc
      CareDx Inc
    •  CountryNorth America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

57 − = 48